{"DataElement":{"publicId":"2180750","version":"1","preferredName":"Transplant Donor Lymphocyte Administered Reason","preferredDefinition":"the reason that a donor lymphocyte infusion is given to a patient during transplant treatment.","longName":"TSPL_DON_LYM_ADM_RSN","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2195868","version":"1","preferredName":"Transplant Donor Lymphocyte Administered","preferredDefinition":"information related to the donor lymphocyte administered during transplant.","longName":"TSPL_DON_LYMPH_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206477","version":"1","preferredName":"Transplant Donor","preferredDefinition":"Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body.:Someone who gives blood or tissue or an organ to be used in another person.","longName":"C12981:C25168","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft","conceptCode":"C12981","definition":"Tissue or organ transplanted from a donor to a recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tissue Donor","conceptCode":"C25168","definition":"Someone who gives blood or tissue or an organ to be used in another person.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F6C6-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2660755","version":"1","preferredName":"Lymphocyte Administered","preferredDefinition":"(LIM-fo-site) A type of white blood cell. Lymphocytes have a number of roles in the immune system, including the production of antibodies and other substances that fight infection and diseases.:Given.","longName":"C12535:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte","conceptCode":"C12535","definition":"White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E73C82-CF0E-5882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDF3EEA0-3EF1-3D67-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2180749","version":"1","preferredName":"Lymphocyte Administered Reason","preferredDefinition":"information regarding the reason lymphocytes were administered.","longName":"LYMPH_ADM_RSN","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"planned per protocol","valueDescription":"planned per protocol","ValueMeaning":{"publicId":"2568297","version":"1","preferredName":"planned per protocol","longName":"2568297","preferredDefinition":"planned per protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7D6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"REEVESD","dateModified":"2015-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22429FA-7108-0DEB-E034-0003BA12F5E7","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"due to relapse","valueDescription":"due to relapse","ValueMeaning":{"publicId":"2568298","version":"1","preferredName":"due to relapse","longName":"2568298","preferredDefinition":"The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"REEVESD","dateModified":"2015-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22429FA-710C-0DEB-E034-0003BA12F5E7","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22429FA-710F-0DEB-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"PTLD","valueDescription":"Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3251848","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder","longName":"3251848","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft.  PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Transplant Lymphoproliferative Disorder","conceptCode":"C4727","definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A771271A-FF2C-B6CD-E040-BB89AD436FA1","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1FF76BEC-86FE-D278-E050-BB89AD432331","beginDate":"2015-09-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-17","modifiedBy":"ONEDATA","dateModified":"2015-09-17","deletedIndicator":"No"},{"value":"Residual Disease","valueDescription":"Residual Disease","ValueMeaning":{"publicId":"2608556","version":"1","preferredName":"Residual Disease","longName":"2608556","preferredDefinition":"Cancer cells that remain after attempts to remove the cancer have been made.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual Disease","conceptCode":"C4809","definition":"Tumor cells that remain in the body following cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B051DEE-4630-0E90-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1FF61771-603E-688E-E050-BB89AD436633","beginDate":"2015-09-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-17","modifiedBy":"ONEDATA","dateModified":"2015-09-17","deletedIndicator":"No"},{"value":"Mixed Chimerism","valueDescription":"Mixed Chimerism","ValueMeaning":{"publicId":"2632131","version":"1","preferredName":"Mixed Chimerism","longName":"2632131","preferredDefinition":"Involving or composed of different kinds.: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed","conceptCode":"C25259","definition":"Involving or composed of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chimerism","conceptCode":"C62582","definition":"The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EDF04B4-18AC-50A1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-04-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1FF61771-6049-688E-E050-BB89AD436633","beginDate":"2015-09-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-17","modifiedBy":"ONEDATA","dateModified":"2015-09-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184326","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"Reason","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1F62-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2240E5E-A751-0BA2-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"REEVESD","dateModified":"2015-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811943","version":"1","longName":"Hodgkin's Lymphoma","context":"CTEP"},{"publicId":"2811944","version":"1","longName":"NonHodgkins Lymphoma","context":"CTEP"},{"publicId":"2811906","version":"1","longName":"Waldenstrom Macrogl","context":"CTEP"},{"publicId":"2811905","version":"1","longName":"Primary Amyloidosis","context":"CTEP"},{"publicId":"2811904","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]}],"AlternateNames":[{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Reason for DLI","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D2251265-C550-1490-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"REEVESD","dateModified":"2015-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}